Skip to content

Don’t invest unless you’re prepared to lose all the money you invest. You are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Category: Calculus Capital News

Calculus Invests in Brouhaha Entertainment

Brouhaha Entertainment was founded by experienced producers: Oscar nominated Gabrielle Tana, Independent film industry pioneer Troy Lum and producer Andrew Mason Founders have successfully produced 27 films and 9 television projects to date, featuring top talent from around the globe Investment will be used to expand the team and fund development in film and particularly … Continued

Calculus exits Mologic – generating up to a 3.6x return for investors

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus successfully exit Mologic by sale to new philanthropic entity Global Access Health London 19 July 2021: Calculus Capital (“Calculus”), pioneers of the tax efficient investment … Continued

Calculus VCT Annual General Meeting 2021

The Annual General Meeting (AGM) of Calculus VCT plc (the “Company”) will be held at 12.30pm on 8 July 2021. The AGM is an important event in the Company’s corporate calendar, providing an opportunity for shareholders to meet the board and put questions to the directors and the investment manager, as well as enabling shareholders … Continued

Calculus invests in Spectral MD

Calculus VCT has invested £0.5m into Spectral MD through an oversubscribed inital public offering onto AIM, on Tuesday 22 June. The Dallas-based firm, which is building notable presence in the UK as part of its product launch effort, produces predictive analytics, proprietary AI algorithms and imaging systems to assist with medical treatment. Spectral MD’s technology, … Continued

Calculus invests in Invizius

The University of Edinburgh spin-out is developing potentially lifesaving products that help reduce complications and high death rates amongst dialysis patients. Incoming institutional investor Calculus Capital has participated in a funding round with existing investors Downing Ventures and Mercia, alongside Solvay Ventures, Scottish Enterprise and Old College Capital Glasgow, Scotland, May 6th, 2021 – Invizius … Continued

Calculus Capital invests in Axol Bioscience following merger with Censo Biotechnologies

Biotech sector-leaders combine tools, talent, and technologies to drive life science discovery forward Merger accompanied by £3.8million ($5.3m USD) investment across existing shareholders and new investors, which will be used to fund recruitment and growth of the business Axol Bioscience Ltd, an established provider of stem cells produced from reprogrammed human blood and tissue cells, … Continued

Celebrating Women in Leadership

Today, on International Women’s Day 2021, we join companies around the globe celebrating the social, economic, cultural, and political achievements of women. International Women’s Day #IWD2021 is an annual reminder to not only recognise and champion greater female representation but also to accelerate gender parity. For this year’s theme #ChooseToChallenge, we believe Calculus leads by … Continued

Support for the creative industries

The creative sector makes a remarkable contribution to the UK economy It is integral to the UK’s economic and social regeneration £400m budget bonus to support the arts British stars dominated at Sunday evening’s Golden Globes virtual awards ceremony with The Crown taking several awards and Sacha Baron Cohen and John Boyega also scooping top … Continued

Calculus invests in eConsult

eConsult Health is the leading online consultation provider to the NHS for primary care With considerable growth over the last year the platform is now live in over 3,200 NHS GP practices and gives millions of patients access to their own GP online. The funding round will be used to accelerate growth in primary care … Continued

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund, Calculus KI EIS Fund, Calculus VCT or Calculus ITS.

An investment into the Calculus EIS Fund, Calculus KI EIS Fund, Calculus VCT or Calculus ITS may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS, VCT or Inheritance Tax (Business Relief) Solution unless you can afford to lose some or all of your capital.

An EIS, VCT or Inheritance Tax (Business Relief) Solution investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within two years for the Inheritance Tax (Business Relief) Solution, three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

I have read and understood this important information

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund, Calculus KI EIS Fund, Calculus VCT or Calculus ITS.

An investment into the Calculus EIS Fund, Calculus KI EIS Fund, Calculus VCT or Calculus ITS may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS, VCT or Inheritance Tax (Business Relief) Solution unless you can afford to lose some or all of your capital.

An EIS, VCT or Inheritance Tax (Business Relief) Solution investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within two years for the Inheritance Tax (Business Relief) Solution, three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

I have read and understood this important information